Investigating glatiramer acetate for relapsing - Remitting multiple sclerosis at the double dose - Is more better? Commentary

Nature Clinical Practice Neurology

Volumn 3, Issue 10, 2007, Pages 540-541

  Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO; STEROID; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; BYSTANDER EFFECT; CELL ACTIVATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INJECTION SITE PAIN; INJECTION SITE REACTION; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR AFFINITY; RELAPSE; SCORING SYSTEM; SHORT SURVEY; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; UNITED STATES;

EID: 34948883491     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0612     Document Type: Short Survey

References (5)

1. Comi G et al. (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-297
2. Butovsky O et al. (2006) Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 103: 11784-11789
3. Vieira PL et al. (2003) Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 170: 4483-4488
4. Bielekova B et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167-1175
5. Comi G (2000) Why treat early multiple sclerosis patients? Curr Opin Neurol 13: 235-240